In patients with coronavirus disease 2019 (COVID-19), the prevalence of pre-existing cardiovascular diseases is elevated. Moreover, various features, also including pro-thrombotic status, further predispose these patients to increased risk of ischemic cardiovascular events. Thus, the identification of optimal antithrombotic strategies in terms of the risk–benefit ratio and outcome improvement in this setting is crucial. However, debated issues on antithrombotic therapies in patients with COVID-19 are multiple and relevant. In this article, we provide ten questions and answers on risk stratification and antiplatelet/anticoagulant treatments in patients at risk of/with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection based on the scientific evidence gathered during the pandemic.

在 2019 年冠状病毒病 (COVID-19) 患者中，原有心血管疾病的患病率升高。此外，各种特征，包括促血栓形成状态，进一步使这些患者发生缺血性心血管事件的风险增加。因此，在这种情况下，根据风险效益比和结果改善确定最佳抗血栓策略至关重要。然而，关于 COVID-19 患者抗血栓治疗的争议问题是多个且相关的。在本文中，我们根据大流行期间收集的科学证据，针对有严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 感染风险的患者提供了 10 个关于风险分层和抗血小板/抗凝治疗的问题和解答。